Efficacy of triple therapy for Helicobacter pylori infection using amoxicillin and clarithromycin and TAK-438 (vonoprazan) which is a novel potassium-competitive acid blocker to the patients treated unsuccessfully with PPI, amoxicillin and clarithromycin.
Not Applicable
- Conditions
- Chronic gastritis
- Registration Number
- JPRN-UMIN000017891
- Lead Sponsor
- Kagawa Prefectural Central Hospital
- Brief Summary
Finally, the eradication rate of H. pylori was 70.2% with a second-line regimen of TAK-438AC in patients for whom the firrst-line treatment with RAC failed. Our study shows promising results of H. pylori eradication with TAK-438-based triple therapy after proton pump inhibitor-based triple therapy failure, based on faster onset of increase in intragastric pH by TAK-438 (vonoprazan). Aliment Pharmacol Ther 2016; 43: 166
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
We excluded patients if they had previously undergone treatment for eradication of H. pylori or gastrectomy; were pregnant; had an allergy to penicillin; had used a PPI, H2 receptor antagonist, adrenocortical steroids, or non-steroidal anti-inflammatory drugs within the month preceding the study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Eradication rate of TAK-438 (vonoprazan)/AC regimen. ITP and PP analysis
- Secondary Outcome Measures
Name Time Method adverse events of TAK-438 (vonoprazan)/AC regimen